On-chip screening for prostate cancer: an EIS microfluidic platform for contemporary detection of free and total PSA

Prostate cancer affects a large part of the western male population. The need for an early and accurate detection is thus a great challenge in common clinical practice, but the lack of specificity of the serum marker PSA (Prostate Specific Antigen) is a serious problem since its increased concentrat...

Full description

Saved in:
Bibliographic Details
Published inAnalyst (London) Vol. 138; no. 18; pp. 544 - 541
Main Authors Chiriacò, Maria Serena, Primiceri, Elisabetta, Montanaro, Alessandro, de Feo, Francesco, Leone, Lorenzo, Rinaldi, Ross, Maruccio, Giuseppe
Format Journal Article
LanguageEnglish
Published England 21.09.2013
Subjects
Abnormalities
Antigens
Cancer
Dielectric Spectroscopy - instrumentation
Electrochemical impedance spectroscopy
Humans
Male
Microfluidic Analytical Techniques - instrumentation
Platforms
Prostate
Prostate-Specific Antigen - analysis
Prostatic Neoplasms - diagnosis
Screening
Serums
Online AccessGet full text

Cover

More Information
Summary:Prostate cancer affects a large part of the western male population. The need for an early and accurate detection is thus a great challenge in common clinical practice, but the lack of specificity of the serum marker PSA (Prostate Specific Antigen) is a serious problem since its increased concentration can be related to several abnormalities. PSA, however, is found in serum in both a free and a complexed form with other proteins and the percentage amount of unbound PSA (the free-to-total PSA ratio) can be employed to distinguish prostate cancer from benign prostatic conditions, and also to predict the future risk of prostate cancer. To improve the operating characteristics of current PSA tests and to provide a clinical tool able to run label-free and sensitive analysis, we thus developed a biosensing platform based on Electrochemical Impedance Spectroscopy (EIS), which allows the contemporary detection of free and total PSA on a single biochip, enabling a quick screening for the risk of prostate cancer thanks to the presence of two different immobilized antibodies specific for the different antigens researched. A low-cost impedimetric platform for on-chip early detection of prostate cancer has been developed, able to perform a label-free and time-saving test for free-to-total PSA ratio.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0003-2654
1364-5528
DOI:10.1039/c3an00911d